Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Flavonoid-based nanomedicines to target tumor microenvironment
Counterintuitively, mice completely defective for the GLP-1 receptor were reported to be protected from high-fat diet-induced peripheral Insulin resistance (177) and, consistently with this, central inhibition of GLP-1R signaling with the antagonist exendin 9-39 improves glucose tolerance and glycaemia (178)
PMID: 38206684
Primary Handling Editor: Karen OLeary, in collaboration with the Nature Medicine team
Shop by Health Benefits Discover our doctor-formulated products collections designed to provide targeted nutritional support for your longevity, optimal health and energy management
To date, two different fixed combinations are available (IglarLixi, insulin glargine/lixisenatide and IdegLira, insulin degludec and liraglutide)
US$ 23.51
US$ 22.90
US$ 25.35
US$ 24.17
US$ 23.01
US$ 24.45
US$ 29.86
US$ 29.01
US$ 20.26
US$ 26.04
